FDA Approves Atzumi, Nasal Powder Formulation of DHE, for Acute Treatment of Migraine

Source: Pharmacy Times articles

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.
Read More